Management of Prostate Cancer: Global Strategies Antonio Alcaraz  European Urology Supplements  Volume 5, Issue 18, Pages 890-899 (November 2006) DOI: 10.1016/j.eursup.2006.08.005 Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 1 Prognostic value of PSA velocity (PSAV) in detecting clinically significant pCA in an early detection setting [13]. Less-aggressive pCA was defined as stage <T2b, Gleason score <7; more-aggresive pCA was defined as stage ≥T2b, Gleason score ≥7. European Urology Supplements 2006 5, 890-899DOI: (10.1016/j.eursup.2006.08.005) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 2 Comparison of percentage of positive surgical margins (PSM), nerve-sparing procedures, and pCA stages in patients treated with RP between 1993 and 2004 (ESPRE study). n=10,553 [24]. European Urology Supplements 2006 5, 890-899DOI: (10.1016/j.eursup.2006.08.005) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 3 Five- and 10-yr survival outcomes after RP in patients with cT3a pCA (n=200) [28]. BPFS: biochemical progression-free survival; CPFS: clinical progression-free survival; CSS: cancer-specific survival; OS: overall survival. Mean follow-up=70.6 mo. European Urology Supplements 2006 5, 890-899DOI: (10.1016/j.eursup.2006.08.005) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 4 Comparison of external beam radiotherapy (EBRT) and RP in terms of survival and disease progression after median follow-up of 67 mo [29]. European Urology Supplements 2006 5, 890-899DOI: (10.1016/j.eursup.2006.08.005) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 5 Long-term risk for first and second skeletal-related events (SREs) in patients with metastatic pCA treated with zoledronic acid (ZA) compared with placebo [61]. European Urology Supplements 2006 5, 890-899DOI: (10.1016/j.eursup.2006.08.005) Copyright © 2006 European Association of Urology Terms and Conditions